Frequently asked clinical questions about NAD+ — direct answers from the published literature

NAD+ is a coenzyme present in every living cell, essential for three non-redundant functions: ATP production via the mitochondrial electron transport chain (accepting electrons from glycolysis and the TCA cycle), sirtuin-mediated gene regulation and mitochondrial biogenesis, and PARP1-dependent DNA repair. In each function, NAD+ is consumed rather than cycled. Blood and tissue levels decline approximately 50% between young adulthood and age 60, based on human biopsy data.^[22]

Common reactions during IV infusion include flushing, nausea, and chest tightness — managed by slowing the infusion rate. Oral precursors NMN and NR are generally very well tolerated; controlled trials at doses up to 3000 mg/day NR reported no moderate or severe adverse events.^[18] Theoretical concerns include a possible interaction between NAD+ and cancer cell proliferation pathways, but no increase in cancer incidence has been observed in published human trials. Long-term safety data beyond 12 weeks remains sparse.

No. Niacin (vitamin B3) is one biosynthetic precursor to NAD+ via the Preiss-Handler pathway, but NAD+ is a dinucleotide coenzyme — structurally and pharmacologically distinct from the vitamin. NAD+ has a molecular weight of 663.4 Da (vs 123.1 Da for niacin), acts as a direct substrate for sirtuins and PARPs, and exerts its effects through mitochondrial and epigenetic pathways that niacin does not directly recapitulate. NMN and NR are more direct precursors with different bioavailability profiles and no flush reaction.

IV NAD+ therapy is intravenous infusion of pharmaceutical-grade NAD+ solution directly into the bloodstream, bypassing gut degradation. Plasma NAD+ and its metabolites are elevated substantially throughout the infusion and detectable in urine post-infusion (Grant et al. 2019, PK pilot, 750 mg over 6 hours).^[9] Used in clinical settings for neuroregeneration research, addiction treatment protocols, and longevity practice. Not FDA-approved for any indication.

IV NAD+ consistently elevates plasma NAD+ during infusion — this pharmacokinetic endpoint is confirmed.^[9] For clinical endpoints: a 50-case series in substance use disorder showed statistically significant reductions in craving, anxiety, and depression;^[11] historical addiction case series reported craving and withdrawal symptom removal.^[12] Large controlled RCTs have not been published as of 2026. The 2025 Nature Metabolism systematic review concluded that NAD+ elevation is achievable but clinical endpoint translation requires further large trials.^[19]

An NAD+ injection is a subcutaneous (SC) or intramuscular (IM) administration of compounded NAD+ solution. It bypasses gut degradation (unlike oral precursors) while requiring less clinical infrastructure than IV infusion. Practitioner protocols range from 100–500 mg SC/IM, 1–3 times weekly. Active registered clinical trials are underway as of 2026; no completed published RCT for SC/IM NAD+ injection is yet available. See NAD+ injection protocols for the full route comparison.

Injectable NAD+ raises blood NAD+ more rapidly than oral precursors by bypassing GI degradation. Published case series from addiction clinics document functional improvements with IV NAD+ protocols.^[11][12] Head-to-head comparisons of SC/IM injectable NAD+ vs oral NMN/NR protocols have not been published in controlled trials as of 2026 — the injectable route is ahead of the formal evidence base. The oral NMN/NR literature provides the strongest controlled efficacy data on NAD+ repletion outcomes.^[5][6][7]

NAD+ is the primary electron carrier in glycolysis and the TCA cycle. Without adequate NAD+, the GAPDH glycolytic step stalls, the NAD+/NADH redox ratio shifts unfavorably, mitochondrial ATP synthesis slows, sirtuin-mediated gene regulation is suppressed, and PARP1 DNA repair capacity is limited — all simultaneously, because all three functions draw from the same pool. The circadian NAMPT/SIRT1/CLOCK feedback loop further means that NAD+ availability oscillates over 24 hours, and disruption of this rhythm impairs metabolic timing.^[14]

NAD+ is the oxidized form that accepts electrons; NADH is the reduced form that donates electrons to Complex I of the mitochondrial electron transport chain. Therapeutic interest centers on raising the total NAD+ pool size, not shifting the ratio directly — sirtuin activity and PARP1 function depend on NAD+ availability, not on the redox ratio per se. The NAD+/NADH ratio matters for metabolic flux but is not the primary target of NAD+ precursor supplementation.

Yes — substantial. Oral NAD+ itself is hydrolyzed in the gut before systemic absorption; oral precursors NMN and NR are more bioavailable but produce NAD+ elevations roughly 2-fold over baseline at daily therapeutic doses.^[4][16] IV infusion delivers NAD+ directly to plasma and produces elevations far exceeding oral dosing. The practical tradeoff is clinical infrastructure requirement and infusion-rate-dependent side effects.^[9][10] IV NR has emerged as a better-tolerated alternative to IV NAD+ in real-world clinical settings.^[10]

Both raise blood NAD+ approximately 2-fold over placebo in a direct comparison RCT (Christen et al. 2026, Nature Metabolism; differences ~49 µM for NR and ~43 µM for NMN, both p<0.001; NAM ineffective).^[16] NMN uses the Slc12a8 transporter for direct cellular uptake in some tissues; NR uses nucleoside transporters. Mechanistic differences may produce tissue-specific advantages not captured by blood NAD+ measurements, but no controlled head-to-head tissue-level human data exists. NR remains a legal dietary supplement; NMN was classified as a drug ingredient by FDA in January 2023.

Published reports cite: plasma NAD+ elevation (confirmed by PK study);^[9] significant reductions in craving, anxiety, and depression in substance use disorder (50-case series);^[11] withdrawal symptom reduction in historical addiction case series.^[12] Observational clinic reports describe cognitive clarity, energy, and mood benefits in wellness contexts — these have not been confirmed in published controlled trials. The 2025 Nature Metabolism review notes the evidence base for clinical endpoints from IV NAD+ specifically remains limited.^[19]

Compounded NAD+ for intravenous or injectable use can be ordered by a licensed physician. Insurance coverage is not standard — IV NAD+ is typically considered experimental or wellness-category and is self-pay. Some addiction-treatment settings may bill under broader substance use disorder treatment codes. The FDA has not approved IV NAD+ for any indication; its use is in the compounded/investigational clinical space.

Clinical reports describe a favorable safety profile when infusion rates are properly controlled (≤2 mg/min). Adverse reactions are rate-dependent — flushing, nausea, chest pressure, and elevated heart rate — and resolve upon slowing or stopping the infusion. No serious adverse events were documented in the published trial and case-series record as of 2025.^[9][10][11] IV NR may offer a more tolerable IV delivery option; a 2026 real-world comparison found IV NR caused only mild reactions vs moderate-to-severe with IV NAD+ at the same 500 mg dose.^[10]

NAD+ biosynthesis slows with age through three mechanisms: rising CD38 NADase expression (2–3-fold increase, driven by SASP cytokines from accumulating senescent cells),^[1][2] declining NAMPT activity in skeletal muscle,^[23] and elevated PARP demand from accumulated DNA damage.^[22] Oral NMN and NR consistently restore blood NAD+ in human RCTs. Whether this restoration reverses aging physiology is under investigation — selective benefits (muscle insulin sensitivity, physical function) are confirmed; systemic functional reversal is not yet established.^[19]

Sirtuins (SIRT1–7) are NAD+-dependent deacylases that regulate mitochondrial biogenesis (SIRT1/PGC-1α), mitochondrial protein function (SIRT3), and DNA break response (SIRT6). NAD+ is consumed in each catalytic cycle, directly linking sirtuin activity to cellular NAD+ availability. Supplementing the NAD+ pool re-activates sirtuin signaling in models of aging.^[13] SIRT1 additionally participates in circadian NAD+ cycling via the NAMPT promoter feedback loop.^[14]

In blood: yes, confirmed across multiple RCTs.^[4][6][7] In skeletal muscle: functional data is consistent with muscle-level benefit (Yoshino 2021 insulin sensitivity,^[5] Igarashi 2022 physical function^[7]). In liver, brain, or adipose tissue in humans: not yet measured in published trials as of 2026. The Yoshino 2021 trial showed muscle benefit without liver benefit — suggesting tissue-selective translation of the blood NAD+ elevation.

Oral NAD+ itself is largely hydrolyzed in the gut by intestinal NADases (CD38, CD73) before systemic absorption. Direct oral NAD+ uptake is minimal. This is why NMN and NR — which are absorbed via dedicated transporters and are more resistant to gut degradation — are the effective oral forms. Gut microbiome additionally converts a portion of NR and NMN to nicotinic acid (Christen et al. 2026),^[16] contributing to but also introducing inter-individual variability in the NAD+ boost from oral precursors.

Clinical trials have tested 250–900 mg/day oral NMN in middle-aged and older adults. A Washington University RCT used 250 mg/day for 10 weeks and showed significant skeletal muscle insulin sensitivity improvements in postmenopausal women.^[5] A multicenter double-blind RCT identified 600 mg/day as the optimal dose for the combination of blood NAD+ elevation and walking distance improvement across 300, 600, and 900 mg/day groups.^[6] Injectable NAD+ protocols in the practitioner literature range from 100–500 mg SC/IM 1–3 times weekly; no completed RCT in this population and route is available as of 2026.

Most common during IV infusion: flushing, chest tightness, nausea, and muscle cramping. Rate-dependent — managed by slowing the drip to 1–2 mg/min. A 2026 real-world comparison found IV NAD+ (500 mg) required mean 97-minute infusion for moderate-to-severe GI and cardiovascular reactions; IV NR (500 mg) required only 37 minutes with mild tingling only.^[10] All reactions resolved post-infusion. Oral NMN/NR side effects are mild — possible GI discomfort at high doses; no flushing; NR demonstrated no serious adverse events at 3000 mg/day in a 30-day controlled trial.^[18]

The peer-reviewed addiction literature documents case series going back to 1961. Braidy et al. (2020, Antioxidants) reviewed O'Hollaren's series of 104+ cases: 500–1000 mg IV NAD+ daily for 4 days removed cravings and withdrawal symptoms — this is historical case series data, not controlled trial data.^[12] Blum et al. (2022) published 50 modern cases with statistically significant craving (p=1.06×10⁻⁹), anxiety (p=5.49×10⁻⁷), and depression (p=1.76×10⁻⁴) reductions.^[11] The mechanistic hypothesis is NAD+-dependent restoration of dopamine pathway homeostasis.

FDA excluded NMN from the dietary supplement category in January 2023 after ChromaDex filed an Investigational New Drug application for it as a drug candidate. This regulatory decision affects retail supplement sales in the US but does not restrict licensed practitioners from using compounded NAD+ or NMN in clinical settings, or from basic and clinical research use. NR remains a legal dietary supplement under DSHEA. Compounded IV NAD+ is administered by licensed practitioners under the compounding pharmacy framework.

No. NAD+ is a dinucleotide coenzyme — two nucleotides joined by a pyrophosphate bond — with molecular formula C₂₁H₂₇N₇O₁₄P₂ and molecular weight 663.4 Da. It is not a peptide, not an amino acid derivative, and not a biologic. It is classified as a small-molecule metabolite. NAD+ has no structural or pharmacological relationship to peptide research compounds or GLP-1 agonist drugs.

Infusion-related reactions (flushing, nausea, chest tightness) typically resolve within 15–30 minutes of slowing or stopping the infusion drip.^[10] Post-infusion fatigue or headache, if it occurs, generally resolves within 24 hours based on clinical reports. No persistent adverse effects have been documented in the published trial record. Oral NMN/NR side effects, where they occur, are mild and transient.

Oral NAD+ itself is poorly absorbed due to gut hydrolysis. Oral precursors NMN and NR are effective at raising blood NAD+ — confirmed across multiple RCTs. NR (as the most-studied oral form) raised blood NAD+ 22–142% dose-dependently at 100–1000 mg/day with strong safety data.^[8] NMN showed comparable blood NAD+ elevation and evidence of functional benefits in muscle^[5][7] and physical performance.^[6][17] The 2025 Nature Metabolism review confirmed consistent blood NAD+ elevation from oral precursors while noting that clinical benefit translation is selective.^[19]

Blood NAD+ elevates within hours of a single IV infusion dose.^[9] With oral NMN or NR, measurable blood NAD+ increases occur within 1–2 hours of ingestion in PK studies; with daily dosing, sustained elevation is confirmed at 4 weeks and maintained through 12 weeks in the Okabe et al. trial (250 mg/day NMN).^[4] Functional endpoints (physical performance, muscle insulin sensitivity) were measured at 10–12 weeks in the major RCTs.^[5][7] NAD+ levels returned to baseline within 4 weeks of stopping supplementation.^[4]

PARP1, the primary enzyme responding to DNA strand breaks, consumes NAD+ per repair event. Supplementing the NAD+ pool expands the substrate available to PARP1. In aged mice, NAD+ repletion restored DNA damage response and improved mitochondrial function (Mendelsohn and Larrick 2017).^[13] The strongest human evidence is from DNA-repair-deficient patients: NR supplementation in Werner syndrome and ataxia-telangiectasia patients produced clinically meaningful improvements in NAD+-repletion-sensitive biomarkers (Bohr 2025).^[21] In healthy adults, the DNA repair benefit from oral NMN/NR has not been directly measured as a trial endpoint.